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ABSTRACT:      32 
 Clostridium difficile is a leading cause of antibiotic-associated diarrhea and the 33 
etiologic agent responsible for C. difficile infection. TcdA and TcdB are nearly 34 
indispensible virulence factors for Clostridium difficile pathogenesis. Given the toxin-35 
centric mechanism by which C. difficile pathogenesis occurs, the selective sequestration 36 
and neutralization of TcdA and TcdB by non-antibiotic agents represents a novel mode of 37 
action to prevent or treat C. difficile-associated disease. In this preclinical study, we used 38 
quantitative enzyme immunoassays to determine the extent by which a novel drug, 39 
calcium aluminosilicate uniform particle size Novasil (CAS UPSN M-1), is capable of 40 
sequestering TcdA and TcdB in vitro. The following major findings were derived from 41 
the present study: Firstly, CAS UPSN M-1 efficiently sequestered both TcdA and TcdB 42 
to undetectable levels. Secondly, we show that CAS UPSN M-1’s affinity for TcdA is 43 
greater than its affinity for TcdB. Lastly, we show that CAS UPSN M-1 exhibited limited 44 
binding affinity for non-target therapeutic proteins. Together, these results suggest that 45 
ingestion of calcium aluminosilicate might protect gastrointestinal tissues from antibiotic- 46 
or chemotherapy-induced C. difficile infection by neutralizing the cytotoxic and pro-47 
inflammatory effects of luminal TcdA and TcdB. 48 
 49 
 50 
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INTRODUCTION 54 
 Clostridium difficile is a leading cause of antibiotic-associated diarrhea (AAD) 55 
and the etiologic agent responsible for C. difficile-associated infection (CDI). CDI 56 
typically starts as a mild diarrhea but rapidly degenerates into a variety of potentially life-57 
threatening conditions, including sepsis syndrome and pseudomembranous colitis (1). In 58 
the United States, approximately 330,000 cases of CDI are estimated each year (2); 59 
however the incidence of C. difficile infection continues to increase (2-3). Increasing CDI 60 
rates highlight that current infection control procedures and treatment options are 61 
insufficient.   62 
 In the healthcare setting, endospore-forming C. difficile are transmitted to patients 63 
via the fecal-oral route (4). Following exposure, the host’s gastrointestinal microbiota 64 
typically either quells a nascent C. difficile infection or suppresses it to sub-clinical levels 65 
(5).  As a result of the latter, approximately 20% of hospitalized adults become 66 
asymptomatic C. difficile carriers, while carriage rates approach 50% for patients in long-67 
term care (6-9). The likelihood of developing CDI increases in patients with dysbiotic 68 
gastrointestinal microbiota, since C. difficile can thrive in the dysbiotic niche (5, 10). This 69 
dysbiosis is often the result of non-specific chemotherapies that are used to treat 70 
conditions unrelated to C. difficile infection (e.g., antibacterial agents or antineoplastic 71 
drugs). 72 
 The antibiotics metronidazole and vancomycin are currently used to treat CDI 73 
(11). Unfortunately, given the conflicting roles of antibiotics in the establishment and 74 
resolution of CDI, C. difficile AAD is recurrent in up to 1 in 5 patients (12). These 75 
already high reoccurrence rates are expected to increase if C. difficile strains with 76 
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intermediate- and complete-resistance to metronidazole and vancomycin emerge (13).  77 
Together, these alarming trends illustrate an urgent need to develop novel and efficacious 78 
therapeutics to treat CDI, including non-traditional therapeutic agents.  79 
 C. difficile is an extracellular pathogen and it typically does not invade host 80 
tissues. While a number of C. difficile-encoded virulence factors are responsible for C. 81 
difficile carriage and pathogenesis, toxin A (TcdA) and toxin B (TcdB) are among the 82 
best-studied (14). Once secreted into the colon, these cytotoxic protein-based enzymes 83 
are translocated across the membrane bilayer and into the cytosol by receptor-mediated 84 
endocytosis (15).  Once inside the cell, these glycosyltransferases trigger altered cellular 85 
transcription, which results in significant cellular apoptosis and tissue remodeling (16-86 
18). TcdA and TcdB are also strongly pro-inflammatory, which exacerbates their effects 87 
on structural and functional changes in tissue integrity (19-20). Together, these 88 
inflammation-related activities contribute to the progressive ablation of gastrointestinal 89 
function that is characteristic of CDI. In animal models, the administration of purified C. 90 
difficile TcdA induces the hallmark symptoms of an acute, pseudomembranous colitis-91 
like condition: edema, gastrointestinal inflammation, cellular necrosis, and gastroenteritis 92 
in the absence of the bacterium (19, 21-23).  The administration of TcdB elicits similar 93 
effects, albeit to a lesser degree (22, 24). As a result, these protein-based enzymes have 94 
been ascribed as nearly indispensible determinants for C. difficile pathogenesis. 95 
 Given the toxin-centric mechanism by which C. difficile pathogenesis occurs, the 96 
selective sequestration and neutralization of TcdA and TcdB by non-antibiotic agents 97 
represents a novel mode of action to prevent or treat C. difficile-associated diseases (25-98 
26).  To date, four C. difficile toxin-binding agents have been examined in pre-clinical 99 
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studies: cholestyramine, colestipol, synsorb 90, and tolevamer (25).  Of these toxin-100 
binding agents, only three have been tested in clinical studies.  Unfortunately, none of 101 
these agents have proven to be as efficacious as traditional antibiotic therapies.  102 
Nevertheless, it is important to continue to develop new candidate therapies.  In this 103 
manuscript, we describe the characterization of CAS UPSN M-1, a novel calcium 104 
aluminosilicate agent that has been developed to selectively bind to and neutralize large 105 
clostridial protein toxins. Calcium aluminosilicate is recognized by the Food and Drug 106 
Administration (FDA) as a Generally Regarded as Safe (GRAS) additive, which can be 107 
supplemented to foods at levels up to 2% (w/w) (27).  108 
 109 
MATERIALS AND METHODS 110 
 111 
Protein-based cytotoxic enzymes and reagents. Lyophilized C. difficile TcdA 112 
and C. difficile TcdB were stored according to the manufacturer’s specification 113 
(Calbiochem, Gibbstown, NJ). TcdA and TcdB were resuspended in 10 mM 2,2-114 
bis(hydroxymethyl)-2,2′,2-nitrilotriethanol (Bis-Tris) buffer (Sigma-Aldrich, St. Louis, 115 
MO) and maintained on ice prior to being assayed.  All other chemicals were molecular 116 
biology grade and stored as recommended by the manufacturer. A SevenMulti 117 
conductivity meter (Mettler Toledo, Columbus, OH) was used for pH measurements. 118 
Putative toxin binding agent. Calcium aluminosilicate uniform particle size 119 
Novasil M-1 (CAS UPSN M-1), the novel sequestering agent used in this study, was 120 
provided by Salient Pharmaceuticals Incorporated (Houston, TX).  121 
Quantitative enzyme immunoassay (qEIA) for toxin quantification.  The 122 
concentration of C. difficile TcdA or TcdB was measured using the Premier Toxins A&B 123 
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enzyme immunoassay (EIA) according to the manufacture’s instructions (Meridian 124 
Bioscience Inc., Cincinnati, OH) except that a series of assay positive control samples 125 
(i.e., TcdA and TcdB reference standards at a range of known concentrations) was 126 
incorporated into each repeated measurement; the concentration of these reference 127 
standards typically ranged from 5 to 20 ng/ml. In brief, the resultant qEIA uses C. 128 
difficile TcdA- and TcdB-specific polyclonal antibodies to capture TcdA and TcdB and to 129 
non-covalently anchor them to the solid-phase EIA support matrix.  Matrix-bound toxins 130 
were subsequently complexed with horseradish peroxidase (HRP)-conjugated mouse 131 
anti-toxin A (monoclonal) or goat anti-toxin B (polyclonal) antibodies, respectively.  132 
After the removal of unbound HRP-antibody conjugates, degradation of urea hydrogen 133 
peroxide by toxin-bound horseradish peroxidase was assayed in the presence of the 134 
reducing co-substrate 3,3′,5,5′-tetramethyl-[1,1′-biphenyl]-4,4′-diamine (TMB).  135 
Phosphoric acid (1 M) was used to arrest the reaction. The terminal chromophore 136 
benzidine-4,4′-diimine (BZDI), an oxidized derivative of TMB, was measured in 137 
arbitrary units (AU) at an optical density of 450 nm (OD450 nm) using an Infinite M200 138 
microplate reader (Tecan US Inc., Durham, NC). The Infinite M200 iControl software 139 
was used to generate custom EIA microplate templates to speed data acquisition and to 140 
ensure accurate sample assignation.   141 
Toxin sequestration assays. This qEIA was used to assess the sequestration (an 142 
aggregate of adsorption and absorption) of large clostridial protein toxins by calcium 143 
aluminosilicate. Unless otherwise indicated, calcium aluminosilicate was suspended up to 144 
a final concentration of 0.5 mg/ml in 10 mM Bis-Tris (pH 6.5) and pre-equilibrated to 145 
37°C in a Thermomixer R shaking incubator (Eppendorf, Hauppauge, NY) equipped with 146 
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a 1.5-ml block with constant agitation at 1,200 revolutions per minute (rpm).  Individual 147 
sequestration reactions were started by the addition of the toxin to a final concentration of 148 
10 ng/ml (TcdA) or 15 ng/ml (TcdB), unless otherwise indicated. Sequestration reactions 149 
were then incubated for 10 min at 37°C with constant agitation at 1,200 rpm in a 150 
Thermomixer R (Eppendorf). The sequestration reaction was stopped when the residual 151 
calcium aluminosilicate and calcium aluminosilicate-bound toxin complexes were 152 
pelleted by centrifugation (2 min at 21,130 × g) in a 5424 bench top centrifuge 153 
(Eppendorf).  Following centrifugation, the clarified supernatant was carefully removed 154 
by aspiration, transferred to a 1.5 ml tube, and chilled on ice prior to toxin quantification 155 
using the qEIA described above.  156 
Heterologous, non-therapeutic protein-binding and SDS-PAGE.  Calcium 157 
aluminosilicate (5 mg/ml) was co-incubated with the SeeBlue Plus2 protein ladder (750 158 
µg/ml; Invitrogen, San Diego, CA), which contains a number of non-therapeutic target 159 
proteins. Samples were incubated at 37°C for 20 min with constant agitation (1,200 rpm). 160 
The reaction was stopped when the residual calcium aluminosilicate and calcium 161 
aluminosilicate-bound protein complexes were pelleted by centrifugation (2 min at 162 
21,130 × g) in an Eppendorf 5424 bench top centrifuge (Eppendorf).  The supernatant 163 
was carefully transferred to a fresh tube and set on ice. The pellet containing the residual 164 
calcium aluminosilicate and calcium aluminosilicate-bound protein complexes was re-165 
suspended in 1 volume buffer and agitated for 20 min at (1,200 rpm). The unbound 166 
calcium aluminosilicate and calcium aluminosilicate-bound protein complexes were 167 
again pelleted by centrifugation (2 min at 21,130 × g). The resultant pellet eluate—168 
including any proteins eluted from the calcium aluminosilicate—was carefully transferred 169 
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to a fresh tube. Negative control samples (i.e., SeeBlue Plus2 devoid of calcium 170 
aluminosilicate) were otherwise treated identically to experimental samples. 171 
 The original supernatant and the pellet eluate were both subjected to 172 
polyacrylamide gel electrophoresis (PAGE).  Samples (15 µl) were loaded into the 1-mm 173 
wells of a NuPAGE Novex Tris-Acetate gel (Invitrogen) using 1× lithium dodecyl sulfate 174 
(LDS) sample buffer (Invitrogen).  Protein electrophoresis was carried out (150 V for 1 h) 175 
in an Xcell SureLock Mini Cell (Invitrogen) and 1× NuPAGE tris-acetate SDS running 176 
buffer (Invitrogen). Proteins were stained using the SimplyBlue Safe Stain (Invitrogen) 177 
according to the manufacturer’s instruction. The results were captured using the 178 
FluorChem HD2 documentation system with a 5 MHz cooled digital CCD camera (Alpha 179 
Innotech). 180 
Biostatistics.  Raw qEIA data were captured using the Infinite M200 i-Control 181 
software, exported to Excel (Microsoft Corporation, Redmond, WA), and analyzed using 182 
Prism (GraphPad Software Inc., La Jolla, CA).  Unless otherwise indicated, data 183 
represent at least three repeated measures. Data are expressed as the mean (x̄) ± either the 184 
standard error of the mean (SEM) or standard deviation (SD), as noted.  Calibration 185 
curves were generated by least-squares regression. ANOVA was used to determine the 186 
statistical significance of the measured differences between treatments.  When significant 187 
differences were detected by ANOVA, Bonferroni tests were performed posthoc in order 188 
explore these differences.  An associated p value of less than 0.05 was considered 189 
statistically significant.  The base-10 logarithm (log10) of each data point was calculated 190 
and a calibration curve for the interpolation of unknowns was generated using least-squares 191 
linear regression.   192 
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 193 
RESULTS 194 
Optimization of a quantitative enzyme immunoassay (qEIA) to detect TcdA 195 
and TcdB. Samples containing known concentrations of TcdA or TcdB were used to 196 
generate standard curves. The standard curves from each of six randomly selected vials of 197 
TcdB are plotted in FIGURE 1.  A one-factor ANOVA found toxin vial-specific effects 198 
were statistically significant (p < 0.0051); however, posthoc comparisons using the 199 
Bonferroni test indicated that—with the exception of one obvious outlier (p < 0.05)—200 
differences between the remaining five curves were statistically nonsignificant (p > 0.05). 201 
For this experimental subset (n = 5), the Pearson product-moment correlation coefficient 202 
(r) indicated a strong, co-linear relationship between toxin concentration and optical 203 
density that was statistically significant between inter-experimental EIA replicates (r = 204 
0.9078, p = 0.0047). Similar results were seen for TcdA (n = 5), although differences 205 
between individual vials of TcdA were statistically nonsignificant (p = 0.8707).  As seen 206 
with TcdB, a strong co-linear relationship between toxin concentration and optical 207 
density was observed.  This co-linear relationship was statistically significant between 208 
inter-experimental qEIA replicates (r = 0.9973, p = 0.0027). In separate experiments that 209 
examined the effect of toxin thermostability, differences in qEIA reactivity following 210 
short-term (e.g., 8 h) incubation on ice were found to be statistically nonsignificant (p > 211 
0.05).  As a result, individual toxin vials were used to conduct multiple sequestration 212 
assays within a single workday and were then discarded. 213 
Data distribution and transformation. The descriptive statistic skewness (g1) 214 
and the Kolmogorov-Smirnov (K-S) normality test were used to examine the data 215 
distribution within the TcdA and TcdB datasets.  While both datasets skewed right 216 
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 Page 10 of 23 
(TcdA: g1 = 0.6626; TcdB: g1 = 1.331), the K-S test indicated that neither exhibited 217 
significant differences from the Gaussian distribution (p > 0.10).  Nevertheless, the base-218 
10 logarithm (log10) of each datapoint was calculated to normalize the data.  Linear 219 
regressions of mean TcdA (n = 4; R2 = 0.968) and TcdB (n = 5; R2 = 0.966) reference 220 
curves are plotted in FIGURE 2. Signal response plateaus were observed at very high 221 
toxin concentrations and very low toxin concentrations (data not shown). 222 
Calcium aluminosilicate does not affect the pH of the qEIA. In order to 223 
determine if calcium aluminosilicate might artificially diminish the sensitivity of the 224 
qEIA by affecting the pH of the buffer system, calcium aluminosilicate was 225 
supplemented to a final working concentration of 0.5 mg/ml in 100 mM Tris (pH 6.5) and 226 
the pH was measured (n = 3) once the mixture was equilibrated to 37°C.  Incorporation of 227 
calcium aluminosilicate up to 0.5 mg/ml did not affect the pH of the buffer system (x ̄ = 228 
6.52, SD = 0.01) when compared to a buffer control that was devoid of calcium 229 
aluminosilicate (x̄ = 6.50, SD = 0.001), as expected. 230 
Effective, dose-dependent sequestration of large C. difficile cytotoxic enzymes 231 
by calcium aluminosilicate. Calcium aluminosilicate was assessed for its ability to 232 
reduce the concentration of large clostridial protein-based cytotoxic enzymes in vitro. 233 
During these dose-response experiments, the concentration of TcdA or TcdB (FIGURE 234 
3) was fixed at 10 ng/ml, while the calcium aluminosilicate concentration was varied 235 
100-fold (i.e., 0.05 mg/ml, 0.075 mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1 236 
mg/ml, 2 mg/ml, 3 mg/ml, and 5 mg/ml). Calcium aluminosilicate efficiently sequestered 237 
TcdA and TcdB in vitro. Differences in mean endpoint OD450 nm between the assay 238 
negative control (i.e., vehicle devoid of TcdA) samples (x̄ = 0.044 AU, SD = 0.001 AU) 239 
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and experimental samples supplemented with calcium aluminosilicate up to 2 mg/ml (x ̄ = 240 
0.049 AU, SD = 0.004 AU), 3 mg/ml (x̄ = 0.049 AU, SD = 0.005 AU), and 5 mg/ml (x ̄ = 241 
0.048 AU, SD = 0.004 AU) were statistically nonsignificant (p > 0.05).  242 
The raw qEIA measurements obtained from experimental samples were converted 243 
to residual toxin concentrations using intra-experimental EIA calibration curves.  244 
Differences in residual TcdA concentration between the assay positive control (i.e., 245 
TcdA-containing samples devoid of calcium aluminosilicate) samples and experimental 246 
samples containing calcium aluminosilicate supplemented up to 0.05 mg/ml (x ̄ = 11.11 247 
ng/ml, SD = 1.82 ng/ml), 0.075 mg/ml (x ̄ = 11.35 ng/ml, SD = 0.22 ng/ml), and 0.1 248 
mg/ml (x ̄ = 10.93 ng/ml, SD = 0.06 ng/ml) were statistically nonsignificant (FIGURE 3).  249 
In contrast, statistically significant differences in residual TcdA concentrations were 250 
measured between the assay positive control and experimental samples containing 251 
calcium aluminosilicate supplemented to 0.3 mg/ml (x ̄ = 8.54 ng/ml, SD = 1.19 ng/ml, p 252 
< 0.05), 0.5 mg/ml (x ̄ = 4.88 ng/ml, SD = 0.80 ng/ml, p < 0.001), 0.75 mg/ml (x ̄ = 3.20 253 
ng/ml, SD = 0.65 ng/ml, p < 0.001), 1 mg/ml (x ̄ = 1.67 ng/ml, SD = 0.71 ng/ml), 2 mg/ml 254 
(x̄ = below the lower limit of detection (bLLD), p < 0.001), 3 mg/ml (x ̄ = bLLD, p < 255 
0.001), and 5 mg/ml (x ̄ = bLLD, p < 0.001).  The lower limit of detection for this qEIA is 256 
approximately 1.4 ng/ml for TcdA and 2.4 ng/ml for TcdB. 257 
The efficiency by which the calcium aluminosilicate calcium aluminosilicate 258 
sequestered TcdB was also explored (FIGURE 3). Differences in endpoint OD450 nm 259 
measurements between the assay negative control (i.e., vehicle devoid of TcdB) samples 260 
(x̄ = 0.047 AU, SD = 0.004 AU) and experimental samples supplemented with calcium 261 
aluminosilicate up to 3 mg/ml (x ̄ = 0.043 AU, SD = 0.001 AU), and 5 mg/ml (x ̄ = 0.041 262 
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AU, SD = 0.002 AU) were statistically nonsignificant (p > 0.05).  As performed with 263 
TcdA, the raw qEIA measurements were converted to residual toxin concentrations. 264 
Differences in residual TcdB concentration between the assay positive control (i.e., 265 
TcdB-containing samples devoid of calcium aluminosilicate) samples and experimental 266 
samples containing calcium aluminosilicate supplemented up to 0.05 mg/ml (x ̄ = 9.07 267 
ng/ml, SD = 0.06 ng/ml), 0.075 mg/ml (x ̄ = 8.75 ng/ml, SD = 0.05 ng/ml), 0.1 mg/ml (x̄ = 268 
9.02 ng/ml, SD = 1.38 ng/ml), and 0.3 mg/ml (x ̄ = 8.44 ng/ml, SD = 0.8 ng/ml) were 269 
statistically nonsignificant (p > 0.05).  In contrast, statistically significant differences in 270 
residual TcdB concentrations were measured between the assay positive control and 271 
experimental samples containing calcium aluminosilicate supplemented up to 0.5 mg/ml 272 
(x̄ = 6.27 ng/ml, SD = 0.36 ng/ml, P < 0.001), 0.75 mg/ml (x ̄ = 5.47 ng/ml, SD = 0.64 273 
ng/ml; p < 0.001), 1 mg/ml (x ̄ = 4.99 ng/ml, SD = 1.23 ng/ml), 2 mg/ml (x ̄ = 3.75 ng/ml; 274 
p < 0.001), 3 mg/ml (x ̄ = bLLD, p < 0.001), and 5 mg/ml (x ̄ = bLLD, p < 0.001).  275 
The protein-binding activity of calcium aluminosilicate.   The selectivity of 276 
calcium aluminosilicate’s protein-binding activity was explored further using a variation 277 
of the C. difficile toxin-binding assay described above.  During these experiments, 278 
calcium aluminosilicate (5 mg/ml) was challenged with a commercial protein cocktail 279 
that contained a number of non-therapeutic proteins, including myosin, bovine serum 280 
albumin, and glutamate dehydrogenase.  A representative SDS-PAGE gel of the 281 
supernatant and the pellet eluate can be found in FIGURE 4.  CAS UPSN M-1 bound 282 
non-therapeutic proteins, but did so with varying efficiency.  Indeed, CAS UPSN M-1  283 
bound myosin and bovine serum albumin inefficiently, while glutamate dehydrogenase 284 
was bound efficiently. Attempts to elute proteins bound to CAS UPSN M-1 were 285 
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unsuccessful (FIGURE 4, lanes 4-5), which suggests that proteins bound to CAS UPSN 286 
M-1 are bound tightly. 287 
 288 
DISCUSSION 289 
The initial toxin concentrations used in this study were selected because they 290 
approximated the median concentration of TcdA (4.3 ng/ml) that is typically found in the 291 
stool of patients with C. difficile-associated diarrhea (range 0.6 ng/ml to 19 µg/ml) (28). 292 
As such, the developed qEIA protocol enabled C. difficile TcdA and TcdB quantification 293 
at clinically relevant concentrations. No hook effect was obvious for either toxin at toxin 294 
concentrations between 5 to 15 ng/ml, which constituted the linear range for this qEIA. 295 
The high-dose hook effect occurs when the antigen negatively affects the binding 296 
capacity of the reporter antibody or when it is added in excess of the reporter antibody 297 
(29). The intra-experimental EIA calibration curves generated using this qEIA protocol 298 
enabled toxin quantification via interpolation and, thus, facilitated the conversion of 299 
optical density measurements to residual toxin concentrations.  Furthermore, given the 300 
high degree of reproducibility, this qEIA supported inter-experimental comparisons 301 
between repeated measurements (e.g., randomized block experiments).  302 
This assay revealed that calcium aluminosilicate efficiently removed both TcdA 303 
and TcdB at physiologically relevant concentrations.  Indeed, calcium aluminosilicate 304 
neutralized TcdA to sub-clinical levels in vitro. Like tolevamer, protein binding by 305 
calcium aluminosilicate does not occur in a generalized or otherwise indiscriminate 306 
fashion and, thus, displays a degree of target specificity. Tolevamer is an anionic, high-307 
molecular-weight polymer (>400 kDa) that was developed to neutralize TcdA and TcdB. 308 
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Tolevamer has been shown to ameliorate CDI-like symptoms in hamsters (30). In 309 
addition, tolevamer has demonstrated therapeutic efficacy in a number of phase II and 310 
phase III clinical studies (25-26). While effective, tolevamer’s cure rate was found to be 311 
inferior to those of vancomycin and metronidazole (26, 31). Surprisingly, however, the 312 
rate of CDI reoccurrence was generally lower with tolevamer than with either 313 
vancomycin or metronidazole (26)  314 
TcdA and TcdB are postulated to be paralogs (32-33).  As a result, these proteins 315 
share significant amino acid sequence similarity to one another—especially at their 316 
amino- and carboxy-terminal regions.   Both toxins share approximately 47% identity to 317 
each other and approximately 68% sequence similarity (data not shown).   Both proteins 318 
are comprised of three well-characterized functional domains (15).  The amino-terminus 319 
of the protein encodes a peptidase C80-type glycosyltransferase domain and a proximal 320 
substrate recognition domain. The hydrophobic middle region is putatively involved in 321 
membrane translocation.  The carboxy terminus of the protein encodes the clostridial 322 
repetitive oligopeptides (CROPS)—also known as cell wall binding (CWB) domains.  323 
The carboxy-terminal CROPS facilitate calcium-dependent host cell recognition (33), and 324 
may also play a role in the sequestration of TcdA and TcdB by calcium aluminosilicate. 325 
Proteins that are evolutionarily and/or structurally related to TcdA and TcdB might also 326 
be viable therapeutic targets for calcium aluminosilicate, however additional research is 327 
required to test this hypothesis. 328 
In addition to the similarities noted above, a number of toxin-specific differences 329 
were also observed.  For example, the lowest experimental concentration of calcium 330 
aluminosilicate for which there was no observable effect was 0.1 mg/ml for TcdA, but 0.3 331 
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mg/ml for TcdB.  The minimum effective concentration (i.e., the threshold dose) for 332 
calcium aluminosilicate was 0.3 mg/ml for TcdA, but 0.5 mg/ml for TcdB.  Under these 333 
conditions, the calcium aluminosilicate concentration that achieved maximum efficacy 334 
(EC100) was 2 mg/ml for TcdA, but the concentration of calcium aluminosilicate that 335 
provided approximately 50% of the maximum effect (EC50) for TcdA was 0.5 mg/ml. In 336 
contrast the EC100 and EC50 for TcdB were 3 mg/ml and 1 mg/ml, respectively. While 337 
calcium aluminosilicate sequesters both protein-based cytotoxic enzymes, these results 338 
suggest that its affinity for TcdA is greater than its affinity for TcdB.  339 
As antibiotic resistant pathogens continue to emerge, the development of non-340 
antibiotic treatment options represents a timely therapeutic approach to CDI management.  341 
Calcium aluminosilicate exhibited potent C. difficile TcdA- and TcdB-neutralizing 342 
activity and selective protein binding in vitro. Given the well-documented safety profile 343 
of calcium aluminosilicate (34), these studies provide in vitro evidentiary support our 344 
hypothesis that ingestion of calcium aluminosilicate might protect gastrointestinal tissues 345 
and accelerate a patient’s recovery from antibiotic- or chemotherapy-induced, C. difficile-346 
associated diarrhea by neutralizing the cytotoxic effects of luminal TcdA and TcdB.  347 
Depending on its relative effectiveness and tolerability during downstream clinical 348 
studies, CAS UPSN M-1, the novel sequestration agent described in this study, may be 349 
used to complement or, possibly, replace existing antibiotic therapies for the treatment of 350 
CDI. However, it is beyond the scope of this current study to examine the biological 351 
effects of calcium aluminosilicate in vivo. 352 
 353 
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FIGURE 1. Untransformed EIA calibration curves. The mean optical density (y-axis) 519 
for each of six randomly selected cytotoxin B EIA calibration curves is plotted as a 520 
function of cytotoxin B concentration (x-axis). The data are expressed as means ± SEM.  521 
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FIGURE 2.  Linear regression of representative logarithm-transformed qEIA 566 
calibration data.  The logarithm (base 10) of the optical density of each reference 567 
standard (y-axis) was determined by EIA and plotted against toxin concentration (x-axis). 568 
Circles denote median calibration data from n repeated replicates. The solid line denotes 569 
linear regression with 95% confidence limits, while dashed lines denote the boundaries of 570 
the calculated 95% confidence interval. Panel A, linear regression of enterotoxin A data 571 
(n = 5, R2 = 0.968). Panel B, linear regression of cytotoxin B calibration data (n = 4, R2 = 572 
0.966).  573 
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FIGURE 3.  The selective and dose-dependent adsorption of C. difficile toxins by 607 
CAS UPSN M-1 in vitro.  CAS UPSN M-1 was supplemented to a final concentration 608 
between 0.05 to 5 mg/ml (100-fold range) (x-axis), while  toxin concentration was fixed 609 
to 10 μg/ml (dashed line).  After a 10-min co-incubation, the mineral-toxin complexes 610 
were removed by centrifugation and the residual concentration of enterotoxin A (blue) 611 
and cytotoxin B (red) was determined by quantitative EIA (y-axis).  The data are 612 
expressed as the means ± SD.  The statistical significance of differences in toxin-specific 613 
binding-ability are reported for each concentration. Abbreviations: ns, statistically 614 
nonsignificant (P >0.05);  **, statistically significant (P < 0.01); ***, statistically 615 
significant (P < 0.001).  616 
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FIGURE 4. Non-therapeutic protein-binding assay.  SDS-PAGE gels illustrating 646 
differential binding of myosin (top panel), bovine serum albumin (BSA) (middle panel), 647 
and glutamate dehydrogenase (GLUD) (bottom panel).  Lane 1, untreated reference 648 
protein (negative control); Lanes 2-3, CAS UPSN M-1-treated protein samples 649 
(duplicates); Lanes 4-5, eluate of protein-bound-CAS UPSN M-1 complexes (duplicates). 650 
White carrots are used to mark lanes that are devoid of a protein band. 651 
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